Impact of cardiovascular involvement on the clinical course of paediatric mitochondrial disorders.
Cardiomyopathy
Heart failure
Mitochondria
Paediatrics
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
31 07 2020
31 07 2020
Historique:
received:
21
05
2020
accepted:
21
07
2020
entrez:
2
8
2020
pubmed:
2
8
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Primary mitochondrial disorders (PMD) are rare conditions resulting in progressive multi-organ failure. Cardiovascular involvement (CVI) has been reported in paediatric patients. However, its age-related prevalence, clinical presentation and prognostic impact are unresolved. We detailed CVI in a cohort of children diagnosed with PMD over two decades at a tertiary referral centre. We enrolled 86 PMD patients (M/F = 30/56; mean age 6.4 ± 8.58 years). CVI was detected in 31 patients (36%), with mean age at onset of 5.7 ± 7.8 years including the pre- and neonatal phase in 14, often representing the first sign of PMD (42% of those with CVI). Heart disease resulted more common in males and in children with specific aetiologies (Barth, TMEM70 and MELAS syndromes). Hypertrophic, non-compaction and dilated cardiomyopathies were the prevalent disorders, although pulmonary arterial hypertension was also found. Adverse cardiac events (heart failure, resuscitated cardiac arrest, ICD/PM implantation, sudden death) occurred in 19% of children with CVI over a follow-up period of 5.4 ± 4.3 years. All-cause mortality was higher in patients with CVI compared to those without CVI (45.1% vs 21.8%; p < 0.01); female sex, age at onset < 5 years, acute heart failure at presentation and diabetes also proved independent predictors of outcome. Cardiovascular involvement occurred in over one-third of children diagnosed with PMD, often at a very early age, and was associated with adverse prognosis. Final outcome of PMD-related CVI was influenced by the specific underlying aetiology, suggesting the need for tailored management of heart failure and sudden death prevention.
Sections du résumé
BACKGROUND
Primary mitochondrial disorders (PMD) are rare conditions resulting in progressive multi-organ failure. Cardiovascular involvement (CVI) has been reported in paediatric patients. However, its age-related prevalence, clinical presentation and prognostic impact are unresolved. We detailed CVI in a cohort of children diagnosed with PMD over two decades at a tertiary referral centre.
RESULTS
We enrolled 86 PMD patients (M/F = 30/56; mean age 6.4 ± 8.58 years). CVI was detected in 31 patients (36%), with mean age at onset of 5.7 ± 7.8 years including the pre- and neonatal phase in 14, often representing the first sign of PMD (42% of those with CVI). Heart disease resulted more common in males and in children with specific aetiologies (Barth, TMEM70 and MELAS syndromes). Hypertrophic, non-compaction and dilated cardiomyopathies were the prevalent disorders, although pulmonary arterial hypertension was also found. Adverse cardiac events (heart failure, resuscitated cardiac arrest, ICD/PM implantation, sudden death) occurred in 19% of children with CVI over a follow-up period of 5.4 ± 4.3 years. All-cause mortality was higher in patients with CVI compared to those without CVI (45.1% vs 21.8%; p < 0.01); female sex, age at onset < 5 years, acute heart failure at presentation and diabetes also proved independent predictors of outcome.
CONCLUSION
Cardiovascular involvement occurred in over one-third of children diagnosed with PMD, often at a very early age, and was associated with adverse prognosis. Final outcome of PMD-related CVI was influenced by the specific underlying aetiology, suggesting the need for tailored management of heart failure and sudden death prevention.
Identifiants
pubmed: 32736646
doi: 10.1186/s13023-020-01466-w
pii: 10.1186/s13023-020-01466-w
pmc: PMC7393884
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
196Références
Cardiology. 2017;137(3):188-192
pubmed: 28441660
Am J Hum Genet. 2013 Aug 8;93(2):211-23
pubmed: 23849775
Pediatrics. 2008 Nov;122(5):1003-8
pubmed: 18977979
Am J Hum Genet. 2013 Nov 7;93(5):906-14
pubmed: 24119684
Pediatrics. 2005 Nov;116(5):1170-7
pubmed: 16264005
Science. 2015 Dec 4;350(6265):aad2459
pubmed: 26785495
Int J Cardiol. 2019 Feb 1;276:14-19
pubmed: 30482630
Eur J Hum Genet. 2011 Jul;19(7):769-75
pubmed: 21364701
Nat Rev Mol Cell Biol. 2016 May;17(5):308-21
pubmed: 26956196
Am J Hum Genet. 2016 Oct 6;99(4):831-845
pubmed: 27640307
Circ Res. 2016 Jun 10;118(12):1960-91
pubmed: 27126807
BMC Pediatr. 2020 Jan 29;20(1):41
pubmed: 31996177
Neurology. 2002 Nov 12;59(9):1406-11
pubmed: 12427892
Mol Genet Metab. 2016 Jul;118(3):178-84
pubmed: 27312126
J Am Coll Cardiol. 2005 Aug 2;46(3):480-7
pubmed: 16053962
Neuromuscul Disord. 2002 Jan;12(1):56-9
pubmed: 11731286
Int J Cardiol. 2012 Mar 8;155(2):305-6
pubmed: 22188990
Eur Heart J. 2003 Feb;24(3):280-8
pubmed: 12590906
Pediatrics. 2004 Oct;114(4):925-31
pubmed: 15466086
Orphanet J Rare Dis. 2014 Aug 20;9:119
pubmed: 25208612
Pediatr Cardiol. 2004 Sep-Oct;25(5):443-50
pubmed: 15185043
Orphanet J Rare Dis. 2013 May 08;8:70
pubmed: 23656970
Trends Mol Med. 2020 Jan;26(1):8-20
pubmed: 31375365
J Multidiscip Healthc. 2015 Jul 29;8:345-58
pubmed: 26251611
Eur Heart J. 2015 Nov 7;36(42):2886-93
pubmed: 26224072
J Inherit Metab Dis. 2015 May;38(3):417-26
pubmed: 25326274
Eur J Heart Fail. 2010 Feb;12(2):114-21
pubmed: 20083621
Semin Fetal Neonatal Med. 2011 Aug;16(4):216-21
pubmed: 21606011
Pediatr Res. 2006 Jan;59(1):21-6
pubmed: 16326995
Pediatr Transplant. 2007 Aug;11(5):560-2
pubmed: 17631029
Nat Commun. 2017 Jun 12;8:15824
pubmed: 28604674
J Med Genet. 2012 Sep;49(9):578-90
pubmed: 22972949